ASX healthcare stocks kept climbing the clinical milestone ladder during the March quarter. Pic: Getty Images <\/p>\n
Entropy advances Phase II clinical trial of TRP-8803 for binge eating disorder
\nLTR\u2019s SPONTAN Phase II pharmacokinetic study fully recruits, with interim PK data expected in Q2 CY26
\nNeurotech initiates Phase III Beyond Harmony trial, while Singular Health expands its commercial footprint in the US<\/p>\n
\u00a0<\/p>\n
Quarterly reporting season is upon us once more for ASX-listed healthcare companies, with updates showing a mix of clinical momentum and financial discipline across the sector.<\/p>\n
This reporting period arrives against a more unsettled macro backdrop, with ongoing geopolitical tensions in the Middle East, macroeconomic pressures and broader market volatility.<\/p>\n
After a prolonged period of underperformance for parts of the healthcare sector, investors are watching closely for signs of genuine clinical progress translating into commercial traction.<\/p>\n
\u00a0<\/p>\n
Entropy Neurodynamics (ASX:ENP)<\/a><\/p>\n Entropy progresses Phase II clinical trial using TRP-8803 for binge eating disorder\u00a0 Entropy has highlighted progress during the March quarter in its Phase II clinical trial using its lead IV therapy TRP-8803 for binge eating disorder (BED), alongside strengthened intellectual property protection and a solid funding position to advance ongoing development.<\/p>\n During the quarter, the first treated patient treated with TRP-8803, alongside supportive psychotherapy, completed the four-week post-treatment assessment with top-line results demonstrating clinically meaningful improvements across multiple symptom domains.<\/p>\n Cohort 1 of the Phase II BED trial completed enrolment of six patients in March with three already fully dosed and the remainder progressing through treatment.<\/p>\n Top-line results are expected this quarter following completion of dosing and four week follow-up later this quarter.<\/p>\n Supporting the program, Entropy also published peer-reviewed Phase 2a data for TRP-8802 (oral), showing an ~80% reduction in binge eating episodes sustained over follow-up, along with improvements in psychological and metabolic markers.<\/p>\n In addition, the company secured Australian patent protection for its precision-controlled IV dosing method underpinning TRP-8803 through to 2042.<\/p>\n Bolstering its cash position Entropy received ~$1.73 million refund under the Australian Government\u2019s R&D tax incentive for FY25.<\/p>\n The company ended the March quarter with $9.1m in cash and funding facilities to support continued clinical execution and upcoming trial activity.<\/p>\n \u00a0<\/p>\n LTR Pharma (ASX:LTP)<\/a><\/p>\n LTR\u2019s SPONTAN Phase II pharmacokinetic study fully recruited with interim PK data on track for Q2 CY26 readout LTR Pharma made solid progress across clinical development, commercialisation and real-world validation of its nasal spray therapy SPONTAN and ROXUS to treat erectile dysfunction (ED).<\/p>\n During the quarter LTR progressed SPONTAN into the dosing phase of its Phase II pharmacokinetic (PK) study reaching full recruitment of 27 participants across three cohorts, with the final cohort progressing through a 15-day dosing phase.<\/p>\n Interim PK results remain on track for release in Q2 CY26 and are expected to support the company\u2019s US Food and Drug Administration (FDA) 505(b)(2) regulatory pathway.<\/p>\n Scientific confidence in SPONTAN was reinforced with Phase I data accepted for podium presentation at the World Meeting on Sexual Medicine 2026, highlighting faster absorption and improved bioavailability versus oral vardenafil, alongside a favourable safety profile.<\/p>\n Real-world use under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) also continued to expand. Prescribing activity under the SAS has now exceeded 1,000 cumulative prescriptions, contributing to ongoing real-world evidence generation.<\/p>\n During the quarter an independent observational case series reported positive real-world outcomes from SPONTAN use in five younger men experiencing erectile difficulties associated with performance anxiety.<\/p>\n On the commercial front, LTR Pharma continued advancing its US strategy for ROXUS via the FDA 503(a) personalised medicine pathway, with partner discussions progressing and a disciplined focus on structuring long-term value-accretive agreements.<\/p>\n Financially, the company remains well-positioned with a cash balance of $24.1m, no debt, and an estimated 13-quarter funding runway.<\/p>\n \u00a0<\/p>\n
\nSecures Australian patent protection for precision-controlled IV dosing method underpinning TRP-8803 through to 2042
\nEnded March quarter with $9.1 million in cash and funding facilities to support continued clinical execution<\/p>\n
\nPhase I SPONTAN data accepted for podium presentation at World Meeting on Sexual Medicine 2026
\nContinued commercial momentum for ROXUS US entry via FDA 503(a) pathway, alongside expanding real-world prescribing\u00a0<\/p>\n